Novo Nordisk reshuffles Executive Management team with two major additions
pharmafile | August 15, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Novo Nordisk, appointment, life sciences, medicine, pharma, pharmaceutical
This month has seen two new additions to Novo Nordisk’s Executive Management team. First of the pair is Camila Sylvest, who has served the company as Senior Vice President and General Manager, China since 2015. Slyvest oversees Novo’s activities across China, Taiwan and Hong Kong. From 1 October, Sylvest will take on the role of Senior Vice President of Commercial Strategy and Corporate Affairs, heading up the unit with responsibility for Novo’s corporate function within marketing, communications, stakeholder relations, sustainability, market access and strategy.
Originally joining the company in 1996, Sylvest has since tackled business areas of increasing size and complexity across Europe and Asia, including pricing, health economics and sales effectiveness.
“During her more than 20 years in Novo Nordisk,” remarked Lars Fruergaard Jørgensen, Novo President and CEO, “Camilla Sylvest has consistently delivered strong business results, fostered strong relations with stakeholders and demonstrated a natural ability to rally her organisations around key priorities. This makes me very confident in her ability to successfully drive our commercial strategies as well as our strategies for developing Novo Nordisk as a responsible corporation focused on the needs of the patients we serve.”
Secondly, Doug Langa (pictured), the firm’s Head of North America Operations and President of Novo Nordisk Inc – appointed to the role in March this year – has been promoted to Executive Vice President. He joined the company in 2011 and previously served as its Senior Vice President of Market Access. Both he and Sylvest will report to President and CEO Jørgensen.
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
